University of Kansas Cancer Center
Kansas City, KS
Accepting patients
QUINTESSENTIAL
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
EXCALIBER - Maintenance
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
- CELMoD
- Randomization
- Post-Autologous Stem Cell Transplant
- Phase 3
Not yet accepting
DURGA-4
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- CAR T Cell
- CD19
- BCMA
- Randomization
- Phase 3
Accepting patients
TECVAYLI
A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma
- CELMoD
- Bispecific Antibody
- BCMA
- Phase 1